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Chemotherapy-induced nausea and vomiting: an overview to inform dietetic practice 1 
 2 
Abstract 3 
Chemotherapy-induced nausea and vomiting (CINV) are common nutrition-impact symptoms 4 
experienced by cancer patients. They exert a detrimental effect on dietary intake, risk of 5 
malnutrition and quality of life. While CINV are primarily managed with medication, 6 
dietitians play an important role in the management of CINV-related complications such as 7 
reduced dietary intake. This review discusses the burden of nausea and vomiting which 8 
cancer patients can experience, including its effect on quality of life, nutrition status, and 9 
treatment outcomes. Implications for dietetic practice include the need to explore the nature 10 
of reported symptoms, identify predisposing risk factors, and to consider the use of a variety 11 
of interventions that are individualised to the patient’s symptoms. There are little clinical data 12 
regarding effective dietetic interventions for nausea and vomiting. In summary, this review 13 
discusses dietetic-related issues surrounding CINV including the pathophysiology, risk 14 
factors, prevalence, and both pharmacological and dietetic treatment options. 15 
 16 
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Introduction 25 
There are multiple chemotherapy agents that can induce nausea and vomiting. However, with 26 
the advent of modern anti-emetics, there has been a significant reduction in the prevalence of 27 
vomiting, with a current estimated incidence of less than 20%.1, 2 Efforts to control nausea in 28 
this setting have been less effective, with up to 60% of patients reporting nausea despite the 29 
use of anti-emetic medication.1 Consequently, nausea remains one of the most distressing 30 
side effects experienced by cancer patients, while vomiting is now of less concern.3-5 In 31 
addition, research has consistently associated chemotherapy-induced nausea and vomiting 32 
(CINV) with adverse effects on dietary intake, risk of malnutrition and quality of life (QoL).6, 33 
7 34 
Dietitians routinely consult with cancer patients experiencing CINV and related symptoms. 35 
The aim of this manuscript is to inform dietetic practice by providing a general overview of 36 
CINV, as well as CINV-specific issues related to clinical nutrition. These include the 37 
pathophysiology,  and management options for CINV, including current medications and 38 
potential dietetic treatment options. 39 
Methods 40 
A literature search was undertaken between January and July 2015 using the following 41 
databases: Medline, Cumulative Index to Nursing and Allied Health Literature, and the 42 
Cochrane Library. Search terms were not limited by timeframe; instead, all searches were 43 
from the date of each database’s inception until July 2015.The bibliographies of relevant 44 
articles were scanned to identify additional articles of interest. The evidence-based guidelines 45 
of the Academy of Nutrition and Dietetics, Dietetics Association of Australia and the 46 
Practice-based Evidence in Nutrition Knowledge Pathway were reviewed for additional 47 
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references. The following search terms were used: (Chemotherapy AND (nausea OR 48 
vomiting OR CINV)) AND ((Risk factors OR prognostic OR predictor) OR (Mechanism OR 49 
pathophysiology OR physiopathology) OR (Nutrition OR malnutrition OR weight) OR 50 
“Quality of life” OR guidelines OR ginger OR protein OR (CAM OR Complementary OR 51 
Alternative)). Only studies published in English with human subjects were included. The 52 
results of this search strategy are detailed in Figure 1 and include the following citations:1-67. 53 
The results of the literature search were sorted based on the headings included in this review 54 
and were used to inform the discussion of each topic.  55 
Defining chemotherapy-induced nausea and vomiting 56 
CINV is a collective term used to describe the presentation of nausea, vomiting or a 57 
combination of both symptoms associated with the administration of cytotoxic chemotherapy. 58 
While nausea and vomiting are related concepts, they involve distinct physiological 59 
mechanisms and are therefore defined separately in Table 1.68 60 
Nausea is a subjective sensation of discomfort, typically associated with the epigastrium, 61 
which might result in vomiting. Due to this subjective nature, the sensation, location, duration 62 
and intensity of nausea reported by patients can vary.30 In addition, multiple nutrition impact 63 
symptoms interlink with nausea such as appetite loss, lack of energy, taste changes and 64 
pain.31 Hence, if a patient experiences nausea, it is prudent to investigate the individual’s 65 
sensations in order to effectively target treatment towards those symptoms. 66 
CINV is further classified as acute, delayed, anticipatory, breakthrough, and refractory. 67 
Exact definitions of acute CINV vary but it is generally considered to be nausea and/or 68 
vomiting that occurs within 24 hours of chemotherapy administration.32 Delayed CINV is 69 
defined as nausea and/or vomiting that occurs after the first 24 hours post-chemotherapy.68 70 
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While this distinction might appear arbitrary, research suggests that differing physiological 71 
processes are involved in the acute phase when compared to the delayed phase.69  72 
Anticipatory CINV is a conditioned response that occurs after previous cycles of 73 
chemotherapy in which nausea and/or vomiting were not adequately controlled. The current 74 
understanding of anticipatory CINV is explained in Pavlovian terms. According to this 75 
framework, a neutral stimulus (e.g. the smell of the hospital, the sight of treating staff) is 76 
coupled with an unconditioned response (CINV), caused by the unconditioned stimuli 77 
(chemotherapy). Once this occurs, a conditioned response develops wherein the formerly 78 
neutral stimulus elicits the same response as the unconditioned stimulus.33 While a 79 
conditioning period is required for this coupling to occur, the length of this period varies 80 
according to the individual and can occur as soon as the second cycle of chemotherapy. 81 
Anticipatory CINV may also cause of certain food aversions, as food eaten during the days 82 
surrounding chemotherapy can be mentally paired with the sensation of nausea.  83 
Breakthrough CINV is nausea and/or vomiting that occurs despite adherence to optimal anti-84 
emetic protocols and is treated by administering additional “rescue” anti-emetic medication.34 85 
Refractory CINV comprises symptoms that occur in subsequent cycles despite delivery of 86 
optimal anti-emetic control in previous cycles.34 If this occurs, additional medication is likely 87 
to be required.  88 
Risk factors 89 
An individual’s risk of developing CINV is influenced by numerous factors (Table 2), which 90 
can be categorised into four broad categories: previous experience with nauseating stimuli 91 
(e.g. previous history of motion or morning sickness); genetic and trait factors (e.g. age and 92 
gender); psychosocial factors (e.g. anxiety); and finally, medical and treatment-related factors 93 
(e.g. dose, type of chemotherapy). The primary determinant of a patient’s risk of 94 
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experiencing CINV is the emetogenic potential of the chemotherapy regimen. In order to 95 
guide anti-emetic therapy, chemotherapy regimens are stratified into the following 96 
classifications based on their emetogenic potential: minimally, fewer than 10% at risk; low , 97 
10% to 30% of patients at risk; moderately, 30% to 90% of patients at risk; and highly 98 
emetogenic chemotherapy regimens, nearly all patients (> 90%) at risk.34, 71  99 
Individual risk factors are associated with different levels of risk. For example, Molassiotis et 100 
al.35 reported that patients with a history of nausea and vomiting (e.g. morning or motion 101 
sickness) were three times more likely to experience CINV (OR 3.2 , 95% CI: 1.29–7.95), 102 
while the odds of experiencing CINV increased by 69% for each incremental increase in 103 
reported pain (OR 1.69, 95% CI: 1.03–2.77). Patients with a greater number of these risk 104 
factors are more likely to experience CINV compared to patients with fewer traits. This has 105 
led to the development of multiple tools designed to predict the risk of CINV by assessing the 106 
cumulative effect of risk factors. For example, Bouganim et al.’s36 tool to predict CINV risk 107 
demonstrated that patients categorized as at high-risk of CINV were three times more likely 108 
to experience symptoms than patients who were considered to be low risk. Predictive tools 109 
such as this are currently being refined and validated in larger populations, but with further 110 
studies these tools could improve symptom control by helping to identify high-risk patients 111 
before chemotherapy begins.   112 
Pathophysiology 113 
The development of CINV is complex; this section briefly describes the pathophysiology in 114 
CINV development. 115 
The trigger site for CINV is thought to be within the gastrointestinal tract. Chemotherapy 116 
agents can directly interact with enterochromaffin cells located within the gastric epithelium,  117 
resulting in the release of the neurotransmitters serotonin and substance P.75 The released 118 
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neurotransmitters then interact with receptors located upon the vagus nerve, which 119 
subsequently transmits afferent signals to the chemoreceptor receptor zone (CTZ), a section 120 
of the brain within the area postrema, via the nucleus tractus solitarius. It is thought that 121 
modern 5-HT3 antagonist medications (e.g. ondansetron) interact with the 5-HT3 receptors 122 
involved in this process, which then mitigates the degree of afferent vagal signalling. Another 123 
neurotransmitter, substance P, is also implicated in the generation of CINV primarily by 124 
binding to NK1 receptors located centrally within the brain. Stimuli transmitted using these 125 
two neuropeptides, as well as stimuli from other neurotransmitters (e.g. dopamine, histamine) 126 
and other regions of the brain (e.g. the amygdala), are processed by the CTZ and vomiting 127 
centre, which then coordinate the relevant musculature to induce a nausea and/or vomiting 128 
response.76 129 
An additional source of afferent signalling is suggested to be via direct interaction with the 130 
area postrema, as this part of the brain has a semi-permeable membrane that enables direct 131 
interaction with emetic stimuli within the blood or cerebrospinal fluid. 132 
Impact on patient 133 
Nutrition status 134 
Malnutrition is both a serious and prevalent concern within the oncology setting.44 Estimates 135 
vary but between 30-50% of the general oncology population experience malnutrition and has 136 
been reported to be as high as 88% in certain populations (i.e. head and neck cancer 137 
patients).45-47 Malnutrition is considered an independent risk factor for mortality, increased 138 
length of stay, secondary infections, and healthcare costs.44, 48, 49 Patients who experience 139 
CINV are particularly susceptible to malnutrition due to the direct effect of nausea and 140 
vomiting (e.g. the expulsion of food) or through behavioural factors (such as avoiding certain 141 
foods in an effort to prevent future bouts of CINV). Furthermore, vomiting can impede 142 
accurate nutrition diagnoses as it can reduce the validity of recorded dietary intake. Both 143 
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nausea and vomiting are considered nutrition impact symptoms that can result in 144 
malnutrition.50-53 Cross-sectional and prospective studies investigating the effect of CINV on 145 
a patient’s risk of malnutrition have reported a significant link.7, 54  146 
For example, in a cross-sectional study of cancer patients undergoing chemotherapy (N=121), 147 
CINV was associated with malnutrition, as assessed using the Patient Generated-Subjective 148 
Global Assessment, demonstrating that the majority of patients with severe CINV were 149 
malnourished.7 Similarly, in a prospective study including 104 chemotherapy patients, 150 
patients that experienced severe acute (mean: 5 vs 8; p=0.003) and delayed nausea (mean: 5.1 151 
vs 8; p=0.017) were associated with higher PG-SGA scores compared to patients who 152 
experienced less severe or no nausea. .54 However, the authors of this study noted that the 153 
anti-emetic regimens prescribed to patients within this study were not congruent with current 154 
guidelines. Therefore, while the observed prevalence might reflect typical clinical practice, 155 
the incidence and severity of CINV within this cohort could be higher than what might be 156 
observed if current anti-emetic recommendations were implemented.  157 
When weight loss was measured instead of malnutrition, similar associations were identified. 158 
In a retrospective analysis of cachectic patients with pancreatic cancer (N=107), the absence 159 
of nausea and vomiting was an independent determinant of weight stabilisation (OR 6.5, 95% 160 
CI: 1.6-27.2; p=0.010).29 Another study in a mixed oncology population (N=254) found that 161 
the prevalence of vomiting was higher in patients that experienced significant weight loss 162 
(>5% usual body weight) compared to patients that experienced minimal weight loss(32% vs 163 
14%, respectively; p=0.005).55  164 
In summary, while few studies have purposely investigated the association between CINV 165 
and malnutrition, the existing literature is consistent in its support of this association. In 166 
8 
 
particular, these studies suggest that in patients who experience CINV, nutritional status 167 
should be actively monitored and managed in order to reduce the risk of malnutrition.  168 
Quality of life (QoL) 169 
QoL is poorer amongst patients who experience CINV, either during the acute or delayed 170 
phase, compared to patients without these symptoms.27, 28 Highly emetogenic chemotherapy 171 
regimens are more likely to reduce QoL than moderately- or low emetogenic regimens. This 172 
detrimental effect on QoL is exacerbated with each additional day of CINV and is often 173 
compounded as treatment progresses, because patients who experience CINV in their initial 174 
cycle of chemotherapy are more likely to report poorer CINV-related QoL in subsequent 175 
cycles.27, 56  This indicates that the burden of CINV might be cumulative and affects future 176 
chemotherapy cycles if not adequately controlled during the first cycle.25, 77  When nausea 177 
and vomiting are measured separately, the adverse effect of nausea on QoL has been reported 178 
to be greater than the effect of vomiting, which is particularly pertinent as the prevalence of 179 
nausea is higher when compared to vomiting.57 This difference in effect on QoL is likely due 180 
to current antiemetic therapy being predominantly effective for controlling vomiting as 181 
compared to nausea.  182 
Physical function 183 
Uncontrolled CINV can lead to a number of potentially serious physical conditions and 184 
CINV-related hospital admissions. Due to the loss of potassium, sodium, chloride and water 185 
resulting from frequent or severe vomiting, CINV might result in dehydration, electrolyte 186 
disturbances, and acid-base imbalances.24 Another concern is the risk of aspiration 187 
pneumonia, a condition where vomitus enters the bronchial tree, resulting in pneumonitis. 188 
This can lead to further complications and in some cases is fatal.24 In severe cases of 189 
vomiting, oesophageal tearing and related bleeding and pain can occur. Nutritional 190 
deficiencies are also a potential issue due to inadequate dietary intake of nutrients secondary 191 
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to nausea and the inability to digest consumed food due to vomiting. These conditions can be 192 
further exacerbated by additional comorbidities.58 Finally, during the 1980s, CINV-related 193 
treatment termination was reported to occur in patients;23 however, it is likely that the 194 
prevalence of CINV-related treatment termination has been significantly reduced due to the 195 
improvement in anti-emetic medications.22, 59 196 
Pharmacotherapy of CINV 197 
Multiple medications prevent and relieve the distressing symptoms of CINV. International 198 
evidence-based guidelines, such as those developed by the Multinational Association for 199 
Supportive Care in Cancer and the National Comprehensive Cancer Network, suggest the 200 
ideal combination and timing of the available anti-emetics, according to the emetogenicity of 201 
the chemotherapy treatment.34, 71 It is now common practice to include this standardised, 202 
combination approach to provide optimal control of CINV. While these medications are 203 
effective in reducing CINV, there is no single medication that offers complete protection 204 
during highly or moderately emetogenic regimens and therefore, the medications discussed 205 
below are administered in combination.34 206 
5-HT3 antagonists such as ondansetron, granisetron and palonosetron are important 207 
components of modern anti-emetic therapy. 5-HT3 antagonists work by binding to the 5-HT3 208 
receptors within the gastrointestinal tract, which consequentially blocks afferent emetic 209 
signalling to the CTZ within the brain. Corticosteroids such as dexamethasone are used for 210 
their incidental anti-emetic attributes and are commonly prescribed in combination with other 211 
anti-emetics.34 The mechanism of action for this class of drug is poorly understood but 212 
suggested mechanisms include the modulation of the capillary permeability of the CTZ, anti-213 
inflammatory effects within the gastrointestinal tract, and the release of endorphins.21 A 214 
relatively new class of anti-emetic medication is NK1 antagonists such as aprepitant and 215 
fosaprepitant. These medications are believed to act centrally within the CTZ by inhibiting 216 
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the actions of the neuropeptide, substance P.60 NK1 antagonists are used in combination, 217 
usually with dexamethasone and a 5-HT3 antagonist. They are most effective for moderate to 218 
highly emetogenic chemotherapy, especially where delayed CINV occurs. Until the 219 
introduction of 5-HT3 antagonists, metoclopramide was one of the primary anti-emetic 220 
medications used to treat CINV. It has been suggested that metoclopramide, as with other 221 
dopamine antagonists such as phenothiazine and butyrophenone, primarily interacts with 222 
dopamine D2 receptors within the central nervous system, eliciting a prokinetic effect on the 223 
gut and therefore regulating gut mobility. However, due to the superiority of the new 224 
generation of anti-emetic therapy and the incidence of extrapyramidal reactions with high-225 
dose metoclopramide, anti-emetic guidelines only recommend metoclopramide for low 226 
emetogenic regimens and as a rescue anti-emetic in breakthrough emesis.34, 71 227 
Dietetic and lifestyle interventions 228 
Dietetic-related interventions 229 
Dietitians regularly recommend a number of strategies to help patients manage their nausea 230 
and vomiting during chemotherapy. Broadly, these are categorised as strategies that involve 231 
modification to meal types and/or composition, behavioural strategies that target the way 232 
food is consumed, and lifestyle or environmental strategies (Table 3).78-80 While many of 233 
these strategies appear intuitive, there are currently no clinical trials that have specifically 234 
investigated the efficacy of these strategies in reducing measures of CINV. Furthermore, 235 
while there are guidelines for the dietetic management of CINV,80, 81 the lack of clinical trials 236 
means that these guidelines largely rely on expert opinion. However, medical nutrition 237 
therapy (MNT) is an intervention delivered by a dietitian that is tailored to the individual’s 238 
need and circumstances and utilises the strategies outlined in table 3. Therefore, despite the 239 
lack of studies specifically investigating dietary interventions for CINV, studies investigating 240 
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MNT as an intervention may provide some evidence for the use of these strategies in the 241 
management of CINV. 242 
44, 82The oncology guidelines of the Academy of Nutrition and Dietetics state that there is 243 
currently strong evidence that MNT improves multiple treatment outcomes in patients 244 
undergoing chemotherapy, radiation or chemoradiotherapy in ambulatory or outpatient and 245 
inpatient oncology settings.82 However, when studies that have investigated the use of MNT 246 
in chemotherapy have been analysed separately from studies that have investigated MNT 247 
during radiotherapy, the evidence remains strong  to suggest that MNT improves clinical and 248 
patient-centred outcomes (e.g. quality of life) in patients receiving radiotherapy but less so in 249 
patients receiving chemotherapy. Updated evidence-based practice guidelines  endorsed by 250 
the Dietetic Association of Australia, state that evidence that MNT during chemotherapy 251 
results in similar improvements in clinical or patient-centred outcomes is currently 252 
insufficient.44 The authors of these guidelines found that while dietary supplements or simple 253 
dietary interventions (e.g. provision of handouts detailing food high protein and energy or 254 
basic nutrition counselling) were able to improve nutritional outcomes such as dietary intake 255 
and weight status, they did not find an improvement in quality of life or survival.  256 
There is preliminary support for the use of MNT as part of CINV management. In a small 257 
study (N=35) of ambulatory cancer patients, nausea modestly improved after a two month 258 
multidisciplinary intervention involving a dietitian as well as a physical therapist, social 259 
worker, nurse, and a physician (no p value reported).20 Furthermore, two randomized 260 
controlled trials that investigated the use of dietary counselling or nutrition supplements in 261 
colorectal and head and neck cancer patients undergoing radiotherapy found that the severity 262 
and incidence of CINV was reduced within participants who received dietary counselling.19, 263 
61 While this was in a population undergoing radiotherapy, the pathways involved in the 264 
generation of nausea and vomiting are thought to be similar to CINV. These studies therefore 265 
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provide preliminary support for the use of dietary counselling for these symptoms. Further 266 
studies are required to investigate the use of MNT during chemotherapy to manage CINV and 267 
assess the effect on clinical outcomes such as survival, length of stay and QoL.  268 
There is limited evidence that CINV is associated with taste changes. One study found that 269 
patients who reported experiencing CINV also reported greater levels of taste changes and 270 
metallic taste.18 The nature of this relationship has not been elucidated, so it is unclear if the 271 
use of MNT to manage taste changes may also provide relief to nausea and vomiting 272 
symptoms. 273 
Protein-rich meal consumption 274 
Preliminary clinical data suggest the consumption of a mixed meal, and in particular, a 275 
protein-rich meal, might improve nausea and vomiting symptoms from a variety of 276 
nauseating stimuli, including chemotherapy. For example, a prospective study (N=143) 277 
reported that patients who did not consume food before chemotherapy were 6.8 times more 278 
likely to experience CINV compared to patients who reported eating meals prior to 279 
chemotherapy.57 Jednak et al.62 examined this effect further in a clinical trial that investigated 280 
the effect of different macronutrients on nausea during pregnancy. The results indicated that a 281 
protein-rich meal significantly reduced nausea symptoms compared to both equicaloric 282 
carbohydrate and fat meals, and non-caloric meals. Subsequently, Levine et al.17 explored this 283 
in 28 cancer patients undergoing chemotherapy and reported that a combination of ginger and 284 
protein supplementation resulted in a significant reduction in CINV. This effect was more 285 
pronounced in the group receiving the highest dose of protein, which indicates that protein 286 
supplementation might have been primarily responsible for the reduction in CINV.  287 
The exact mechanism for this is unclear but it has been observed that during exposure to 288 
nauseating stimuli, the electrical rhythm of the stomach becomes dysregulated.17 The 289 
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ingestion of a meal maintains the normal physiological rhythm of the stomach, which might 290 
in turn reduce symptoms of nausea and vomiting. The observed superiority of protein in 291 
reducing nausea symptoms is attributed to its effect on gastrin secretion, which is believed to 292 
normalise gastric activity.16 However, while the current evidence is supportive, further 293 
studies that include larger sample sizes are required, particularly in the chemotherapy setting. 294 
Ginger supplementation 295 
In vitro and animal research indicate that compounds within ginger might exert several 296 
effects on pathways relevant to CINV. These include 5-HT3 receptor antagonism and the 297 
modulation of gastrointestinal motility and gastric emptying rate.14  In a recent systematic 298 
literature review, seven clinical trials were included that tested doses between 0.5-2g of 299 
ginger capsules.15 The results provide equivocal evidence, with two studies reporting no 300 
effect,13, 63 three finding some effect,12, 64, 83 and two studies in favour but with caveats that 301 
reduce the real world application of these results.10, 65 Our review also identified multiple 302 
limitations within the literature such as a lack of control for anticipatory nausea and 303 
prognostic factors that might influence individual CINV response, inconsistent use of 304 
standardized ginger formulations and validated questionnaires, and the use of potentially 305 
suboptimal dosing regimens. Hence, while some evidence supports ginger as an adjuvant 306 
anti-CINV therapy, existing limitations must be addressed before firm recommendations for 307 
its use can be made.  308 
Additional complementary therapies 309 
Several additional complementary therapies have demonstrated varying degrees of efficacy. 310 
These include yoga, progressive muscle relaxation, massage, aromatherapy, hypnosis, 311 
exercise, education programs, and acupuncture-point stimulation.8, 9, 66, 67 However, while 312 
many of these therapies are likely to be low-cost and have minimal side effects, further trials 313 
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are required to address limitations within the literature such as small sample sizes and 314 
inconsistent results.  315 
Conclusion 316 
In summary, CINV poses a significant burden to patients undergoing chemotherapy with the 317 
potential to result in further medical complications, reduce QoL, and  increase the risk of 318 
malnutrition. While some evidence of a benefit from dietary intervention using MNT or 319 
protein rich meals exists further research is required.   320 
 321 
 322 
 323 
 324 
 325 
 326 
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 328 
 329 
 330 
 331 
 332 
 333 
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